About: Identification of Repurposal Drugs and Adverse Drug Reactions for Various Courses of Coronavirus Disease 2019 (COVID-19) Based on Single-cell RNA Sequencing Data

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Identification of Repurposal Drugs and Adverse Drug Reactions for Various Courses of Coronavirus Disease 2019 (COVID-19) Based on Single-cell RNA Sequencing Data Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Identification of Repurposal Drugs and Adverse Drug Reactions for Various Courses of Coronavirus Disease 2019 (COVID-19) Based on Single-cell RNA Sequencing Data
Creator	Huang, Canhua Wu, Min Guo, Kai Hur, Junguk Pu, Qinqin Wang, Zhihan
Source	ArXiv
abstract	With more than 3.8 million people infected Coronavirus Disease 2019 (COVID-19), caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), poses a critical threat to human health. There is no proven vaccine or specific drug to date, which highlights the urgent need for rapid development of therapeutics for COVID-19. To identify potentially repurposable drugs, we employed a systematic approach to mine candidates from U.S. FDA approved drugs and pre-clinical small-molecule compounds by integrating the gene expression perturbation data by chemicals from the Library of Integrated Network-Based Cellular Signatures (LINCS) project with publically available single-cell RNA sequencing dataset from mild and severe COVID-19 patients. We identified 281 FDA approved drugs that have the potential to be effective against SARS-CoV-2 infection, 10 of which are currently undergoing clinical trials to evaluate their efficacy against COVID-19. In conclusion, we have identified a list of repurposable anti-SARS- CoV-2 drugs using a systems biology approach.
has issue date	2020-05-16(xsd:dateTime)
has license	arxiv
sha1sum (hex)	370c6ed5e4e1e80255d7dcc5b93473d474abbe5b
resource representing a document's title	Identification of Repurposal Drugs and Adverse Drug Reactions for Various Courses of Coronavirus Disease 2019 (COVID-19) Based on Single-cell RNA Sequencing Data
resource representing a document's body	covid:370c6ed5e4e1e80255d7dcc5b93473d474abbe5b#body_text
is schema:about of	named entity 'U.S.' named entity 'employed' named entity 'specific' named entity 'Drugs' named entity 'Drug' named entity '2019' named entity 'data' named entity 'COVID-19' named entity 'rapid' named entity '2019' named entity 'proven' named entity 'COVID-19' named entity 'Reactions' named entity 'RNA sequencing' named entity 'clinical trials' named entity 'Network-Based' named entity 'systems biology' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'SARS-CoV-2' named entity 'vaccine' named entity 'single-cell' named entity 'infection' named entity 'COVID' named entity 'mild' named entity 'TCM' named entity 'emetine' named entity 'COVID' named entity 'Adverse Event' named entity 'coronavirus disease' named entity 'small-molecule' named entity 'drug repurposing' named entity 'macrophage' named entity 'immune cell' named entity 'MTOR' named entity 'BALF' named entity 'expressed genes' named entity 'BALF' named entity 'protein-protein interactions' named entity 'niclosamide' named entity 'therapeutic agents' named entity 'heatmap' named entity 'SARS-CoV-2' named entity 'viruses' named entity 'RNA virus' named entity 'DNA methylation' named entity 'p38 MAPK' named entity 'Gene Expression Omnibus' named entity 'lopinavir/ritonavir' named entity 'Epithelial' named entity 'infection' named entity 'CD8A' named entity 'clinical trials' named entity '250,000' named entity 'COVID' named entity 'highly contagious' named entity 'agonist' named entity 'preclinical' named entity 'niclosamide' named entity 'BALF' named entity 'p-value' named entity 'immune thrombocytopenia' named entity 'MS4A1' named entity 'phase II trial' named entity 'fostamatinib' named entity 'CD4+ T cell' named entity 'MERS' named entity 'post-marketing' named entity 'viruses' named entity 'cardiac ischemia' named entity 'Ebola' named entity 'chemotherapy' named entity 'randomized clinical trials' named entity 'receptor antagonist' named entity 'NK cells' named entity 'lopinavir/ritonavir' named entity 'PCA' named entity 'scRNA-seq' named entity 'ADRs' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'Principal component analysis' named entity 'ABT-737'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software